35
TBL on Hypertension Therapeutics Assoc Prof Dr Kwa Siew Kim Family Medicine Dept IMU April 2011 Semester 8

TBL on HT Therapeutics

Embed Size (px)

DESCRIPTION

by Prof Kwa (IMU)

Citation preview

Page 1: TBL on HT Therapeutics

TBL on Hypertension Therapeutics

Assoc Prof Dr Kwa Siew KimFamily Medicine Dept

IMU

April 2011 Semester 8

Page 2: TBL on HT Therapeutics

2

Pre-requisites

• Before you embark on this TBL, revisit the lectures on hypertension treatment in Phase 1

• You should also read up the latest 2008 Malaysian Clinical Practice Guidelines (CPG) on Management of Hypertension

Page 3: TBL on HT Therapeutics

3

Revision activity 1:

How would you classify hypertension?What are the co-morbidities that would

affect the management of hypertension?What are the common medications

prescribed for hypertension?What are the common side effects?

Page 4: TBL on HT Therapeutics

4

Revision activity 2:

How would you treat hypertension in the following special cases? children, elderly, pregnant women Chronic disease: hypertension, diabetes,

stroke, LVH, IHD, heart failure, renal disease, connective tissue disease, peripheral vascular disease

Accelerated/emergency hypertension

Page 5: TBL on HT Therapeutics

5

Background Reading

1. Clinical Practice Guidelines: Management of Hypertension. MOH/P/PAK/156.08 (GU). 3rd Edition Feb 2008. Ministry of Health Malaysia, Academy of Medicine of Malaysia, Malaysian Society of Hypertension. http://www.malaysianheart.org/section.php?sid=23&pb=Normal (accessed on 28.2.11)

2. D Gareth Beavers, Gregory YH Lip, Eoin O’Brien. ABC of Hypertension. 5th Ed. BMJ Books. Blackwell Publishing. (Available in the IMU library is the 5th Edition published in 2007)

Page 6: TBL on HT Therapeutics

6

0

10

20

30

40

50

60

1996 2006 2016

Prevalence of hypertension in Malaysians aged 30 years and above

42.6 %

29.9 %

14.4%

1986

?? ?

Page 7: TBL on HT Therapeutics

7

What does NHMS III show?

• Prevalence of hypertension has increased

• But there is little difference in the rate of awareness and rate of BP control in the hypertensive population

• Rate of blood pressure control remains poor (26%) although more diagnosed patients are prescribed with medication for hypertension

Page 8: TBL on HT Therapeutics

8

CVD Risk Factors

• Hypertension*• Diabetes mellitus*• Dyslipidemia*• Obesity* (BMI >30 kg/m2) * Components of the metabolic syndrome• Cigarette smoking• Physical inactivity• Microalbuminuria or estimated GFR <60 ml/min• Age (older than 55 for men, 65 for women)• Family history of premature CVD (men under age 55 or

women under age 65)

Page 9: TBL on HT Therapeutics

9

Benefits of Lowering BP

Average Percent Reduction

• Stroke incidence 35–40%

• Myocardial infarction 20–25%

• Heart failure 50%

Page 10: TBL on HT Therapeutics

10

State of HPT Management

• In general, management of hypertension is poor despite awareness and knowledge

• only 1/5 of hypertensive patients are identified

• 1/5 are treated

• 1/5 are treated to target

Page 11: TBL on HT Therapeutics

11

What is our objective?

• At the end of this session, students should be able to manage the hypertension in the primary care setting based on therapeutic guidelines

Page 12: TBL on HT Therapeutics

12

• Recognise the different co-morbidities with hypertension seen in primary care

• List the common groups of medication prescribed for hypertension

• Describe the mode of action of the drug groups and its side effects

• Discuss and provide answers to the clinical scenarios in “Clinical trigger”

• Summarise the learning issues in “Revision activity”

TBL-your tasks are to:

Page 13: TBL on HT Therapeutics

13

KEY MESSAGES: CLINICAL PRACTICE GUIDELINEON HYPERTENSION, 2008

1. Definition of hypertension: persistent elevation of BP of >140/90 mmHg

2. Prevalence of hypertension in Malaysians > 30 years was 42.6% in 2006

3. 64% of HPT in Malaysia undiagnosed. Do opportunistic BP at every encounter

4. Not treated or poorly treated HPT leads to increased cardiovascular, cerebrovascular and renal morbidity and mortality

5. BP of 120 to 139 over 80 to 89 mm Hg is defined as prehypertension and should be treated in certain high risk groups

Page 14: TBL on HT Therapeutics

14

KEY MESSAGES: CLINICAL PRACTICE GUIDELINE

ON HYPERTENSION, 2008

6. Lifestyle changes for all HPT/ prehypertension

7. Base drug treatment on global vascular risks 8. For new cases with no complications, first

line monotherapy includes all except BB9. Only 26% of Malaysians on treatment reach

target BP (<140/90 mmHg). 10. Combination therapy is often required to

achieve target and may be instituted early

Page 15: TBL on HT Therapeutics

SUMMARY OF SOME RECOMMENDATIONS

From 3rd Malaysian CPG

Page 16: TBL on HT Therapeutics

16

Measurement ofBlood Pressure

• mercury sphygmomanometer is the gold standard

• Take BP in both arms, use higher reading• Take lying and standing • systolic drop of >20 mmHg is considered a

significant postural drop• Home BP measurement useful to monitor control • empowers patient with BP control and may

improve compliance

Page 17: TBL on HT Therapeutics

17

HPT Emergencies

• systolic BP >210 and or diastolic BP >120

• admit

• Useful drugs are – Captopril– Nifedipine – Labetalol– Hydralazine, etc

Page 18: TBL on HT Therapeutics

18

Management of SevereHypertension

• Hypertensive urgencies– reduce BP slowly by 25% over 24 hours but

not lower than 160/90 mmHg

• Hypertensive emergencies– Reduce BP rapidly by 25% over 3 to 12 hours

but not lower than 160/90 mmHg

• NEVER give nifedipine sublingual

Page 19: TBL on HT Therapeutics

19

Hypertension and Diabetes Mellitus

• Rx when BP is persistently >130/80

• Target to <130/80

• If albuminuria, treat with ACEI even if BP normal

• Lower BP to <125/75 if proteinuria >1g/24 hours

• ACEI preferred to ARB unless cough

Page 20: TBL on HT Therapeutics

20

Hypertensionand Stroke

• BP most important predictor for stroke • CCB are better to protect against stroke

compared to diuretic and/or BB • ACEI + diuretic has been shown to reduce

stroke recurrence in both normotensive and hypertensive patients

• morbidity and mortality from further strokes significantly lower in patients receiving ARBs compared with CCBs

• In haemorrhagic stroke, avoid lowering BP in the first few days of accelerated hypertension or hypertensive emergencies

Page 21: TBL on HT Therapeutics

21

Hypertension in the Elderly• Target BP level same as for the young < 140/90• Those with high systolic hypertension can reduce

SBP to below 160 mmHg initially • Weight loss and salt reduction effective because of

their greater sensitivity to sodium intake• All 5 major classes of drugs (diuretics, BB, CCBs,

ACEIs and ARBs) reduce CVD events in elderly• But elderly more sensitive to diuretics and CCB• ACEI is drug of choice for those with concomitant

left ventricular systolic dysfunction, post myocardial infarction or diabetes mellitus.

• Standing BP should be measured to detect postural hypotension

Page 22: TBL on HT Therapeutics

22

Drug Classes in HPT

• Diuretics• ACEI / ARB• Calcium channel blockers• β blockers• α blockers• Combined α β blockers• Centrally-acting drugs-methyldopa, moxonidine • Direct renin inhibitor (Aliskiren)-new kid on the

block

Page 23: TBL on HT Therapeutics

23

Effective combination• ß-blockers +

diuretics

• ß-blockers + CCBs

• CCBs + ACEIs

• ACEIs + diuretics

• ACEI/ARBs + diuretics

• Benefits proven in the elderly (diuretics & CCB), cost-effective.

• Relatively cheap, appropriate for concurrent CHD.

• A p p r o p r i a t e f o r c o n c u r r e n t dyslipidaemias and diabetes mellitus.

• Appropriate for concurrent heart failure, diabetes mellitus and stroke.

• Appropriate for concurrent heart failure, left-ventricular hypertrophy and diabetes mellitus.

Page 24: TBL on HT Therapeutics

24

Choice of HPT drugs • Dyslipidaemia- ACEI & ARB, CCB• LVH- ARB/ACEI • Diabetes- ACEI & ARB, CCB, diuretics • Elderly- diuretics & CCB• Stroke- CCB (10 prevention) & ACEI (post stroke)• CHD & Angina- ß-blockers & long acting CCB• LV dysfunction & post MI- ß-blockers & ACEI• Heart failure- ACEI & diuretics (ß-blockers -

metoprolol, bisoprolol, carvedilol (alpha and beta))• Proteinuria- ACEI & ARB• Benign prostate enlargement- α blockers• HPT in pregnancy- methyldopa, labetalol

Page 25: TBL on HT Therapeutics

25

Some contraindications

• Diuretics: gout ?dyslipidaemia, ?diabetes

• ACEI/ARB: bilateral renal artery stenosis

• ß-blockers: asthma, PVD, ?DM ?dyslipidaemia

• Avoid using short acting CCB (nifedipine) in CHD and unstable angina

• Be careful about BP lowering immediately after stroke

Page 26: TBL on HT Therapeutics

26

Hypertension Cases for Discussion

• There are 2 OBAQ

• There are 6 cases for discussion

• Divide into your 2 groups

• Each group is to work through ALL cases

• You can use the references provided to guide you through the cases

Page 27: TBL on HT Therapeutics

27

Work through these: OBAQ 1

• A 28-year-old man is found to have a BP reading of between 130/82-139/88 mmHg

• This is confirmed on two further occasions

What is the most appropriate diagnosis?

A.Stage 3 Hypertension

B.Stage 2 Hypertension

C.Stage 1 Hypertension

D. Prehypertension

E. Normal

Page 28: TBL on HT Therapeutics

28

• A 70-year-old man is diagnosed with hypertension

• His BP reading is 186/74mm Hg

• He also has BPH

What is the most appropriate BP therapy?

A. Alpha blockers

B.Angiotensin Receptor Blockers

C.Angiotensin Receptor Inhibitors

D.Beta blockers

E.Thiazide diuretics

OBAQ 2

Page 29: TBL on HT Therapeutics

29

Case study 1 – Hypertension and the Elderly

• Mr. Ismail is a 72-year-old Malay man who has 3 repeated blood pressure reading of 180/80 mm Hg despite lifestyle changes. He is asymptomatic and does not have any end organ damage from hypertension.

Questions:• What condition does he have?• Would he benefit from pharmacological

treatment? Give reasons for your answer.• Which drug(s) is suitable?

Page 30: TBL on HT Therapeutics

30

Case study 2 – Hypertension and pregnancy

• 28-year-old primigravida who has a pre-pregnancy blood pressure reading of 100/60 mm Hg. Blood pressure reading at 24 weeks’ gestation is sustained at 130/82.

Question:• Does she have PIH?• For hypertension in pregnancy, which anti-

hypertensive drug(s) would you advise? Give reasons for your choice

Page 31: TBL on HT Therapeutics

31

Case 3: 57 years old Malay contractor • Severe hypertension started on Rx with atenolol 100

mg bd and nifedipine 20 mg tds • BP was uncontrolled at 190/110 mm Hg. • Started on hydrochlorothiazide 25 mg om 3 days ago• Sudden onset of right knee pain on waking up • On examination, BP is 170/100 mm Hg. Pulse is 54

beats per min. BMI 35 WC 110 cm• Right knee joint: red, swollen, hot, very tenderQuestions:What is the cause of his knee arthritis?How would you manage his hypertension?He develops angina. Would you offer him aspirin for

secondary prevention?

Page 32: TBL on HT Therapeutics

32

Case study 4 – Hypertension and Comorbid conditions

• Muthusamy is a 48-year-old smoker with gout, hypertension, dyslipidaemia and previous MI

• His wife is asthmatic and his son has eczema • He is on treatment with metoprolol 50 mg daily.

His blood pressure reading is between 140/90- 160/100 mm Hg

Questions:• Comment on his hypertension treatment.• What hypertensive drug(s) are suitable for him?

Page 33: TBL on HT Therapeutics

33

Case study 5 – ACEI

• Mr. Lim, a 52-year-old diabetic was prescribed ACEI for newly-diagnosed hypertension.

• His initial serum creatinine prior to treatment is 100 μmol/l

• One week later, his serum creatinine is 150 μmol/l

Questions: Explain why. What should you do?

Page 34: TBL on HT Therapeutics

34

Case study 6 – Hypertensive Urgencies

• Mr. Lim, a 52-year-old asymptomatic man was incidentally found to have BP of 190/112 mm Hg repeated three times

• He was treated with sublingual nifedipine and his BP dropped to 100/60 mmHg

• He then developed left-sided hemiplegiaQuestions:• What went wrong? Comment on his

hypertension management.

Page 35: TBL on HT Therapeutics

35